NEW SPINAL FLUID BIOMARKERS FOR ALZHEIMER DISEASE.

An international group of researchers (Geert Of Meyer, John Q. Trojanowski and other) have developed a simple test that identifies in spinal fluid : beta amyloid protein 1-42 and axon tau 181P phosphorilated protein in 90-100% of individuals with Alzheimer’s Disease (AD). Same biomarkers were identified in people with moderate cognitive deterioration (72%) and cognitive healthy groups (36 %). The results that appear today in Archives of Neurology (Diagnosis-Independent Alzheimer Disease Biomarker Signature in Normal Cognitively Elderly People), were validated in concomitant autopsies carried out in 68 patients (64 +/94% of Sensibility), in those that the mentioned biomarkers were also identified. In 57 additional patients with moderate cognitive deterioration, followed during 5 years in those the test showed a sensibility of 100%, was inferred that they were progressing toward AD, suggesting that AD can be diagnosed early (one decade or but, before the symptoms appear). The test is added to others like new PET brain scans that seemingly detect brain beta-amyloid plates.

BIOMARCADORES EN LCR PARA DIAGNOSTICAR ENFERMEDAD DE ALZHEIMER.

Un grupo internacional de investigadores (Geert De Meyer, John Q. Trojanowski y otros), han desarrollado un test sencillo que identifica en Liquido Cefalorraquídeo (LCR): proteína β-amiloide 1-42 y proteína axonal fosforilada tau181P, en 90-100% de casos de individuos con Enfermedad de Alzheimer (EA). Las mismas proteínas fueron identificadas en personas con deterioro cognitivo moderado (72 %) y grupos cognitivos normales sanos (36 %). Los resultados que aparecen hoy en Archives of Neurology (Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People), fueron validados en concomitantes autopsias realizadas a 68 pacientes (64 +/94 % de Sensibilidad), en los que se también se identificaron los biomarcadores mencionados. En 57 pacientes adicionales con deterioro cognitivo moderado, seguidos durante 5 años en los que el test mostro una sensibilidad de 100%, se infirió que estaban progresando hacia EA, sugiriendo que esta enfermedad puede ser diagnosticada tempranamente (una década o mas, antes que aparezcan los síntomas). El test se agrega a los nuevos PET scans cerebrales que aparentemente detectan placas de beta-amiloide cerebral.